Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
Welcome,         Profile    Billing    Logout  
 10 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruemmele, Frank M
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
IMMUNOBIOTA, NCT02614911: Characterization of Phenotype and Genotype of Early Onset Enteropathies

Recruiting
N/A
1445
Europe
Biological sampling
Imagine Institute
Inflammatory Bowel Disease
06/54
06/54
Jacobson, Kevan
ViDiPeC-2, NCT03999580: The Vitamin D in Pediatric Crohn's Disease ( )

Recruiting
3
316
Canada
vitamin D3, cholecalciferol
Jantchou Prevost
Crohn Disease
12/23
12/24
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
NCT03630146: iPeer2Peer Program for Adolescents With Inflammatory Bowel Disease

Completed
N/A
150
Canada
iPeer2Peer program, Waitlist control
The Hospital for Sick Children
Inflammatory Bowel Diseases
03/22
03/22
CIDsCaNN, NCT02308917: The Canadian Children Inflammatory Bowel Disease Network

Recruiting
N/A
2400
Canada
The Hospital for Sick Children, Children's Hospital of Eastern Ontario, British Columbia Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, IWK Health Centre, Montreal Children's Hospital of the MUHC, St. Justine's Hospital, Health Sciences Centre, Winnipeg, Manitoba, Eastern Health, Children's Hospital of Western Ontario, McMaster Children's Hospital
Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
04/26
04/26
DEIVA, Kumaran
IDAR, NCT05545384 / 2022-002385-32: Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial

Recruiting
3
86
Europe
Immediate Azathioprine (1st attack), Immediate Rituximab (1st attack), Standard of care
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Acute Demyelinating Syndrome
04/27
04/30
PASTA, NCT04873583 / 2021-005571-39: High Dose Steroids in Children With Stroke

Recruiting
3
70
Europe, RoW
Methylprednisolone, Solu-Medrol, Prednisolone, Spiricort
Insel Gruppe AG, University Hospital Bern, University of Bern
Paediatric Stroke
08/25
07/26
TIM-DePisT, NCT05946486: Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

Not yet recruiting
3
174
Europe
immunomodulatory treatment by rituximab
University Hospital, Bordeaux
Mental Disorder
01/26
12/26
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27
REMYELIKIDS, NCT05258396: Exploring Cortical Remyelination in Children with Multiple Sclerosis

Recruiting
N/A
40
Europe
MRI without injection of contrast product
Assistance Publique - Hôpitaux de Paris
Children with Multiple Sclerosis
09/25
09/25
Lionetti, Paolo
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
NCT06324500: Prognostic Role of Bowel Ultrasound Scan in Children Affected by Acute Severe Colitis

Recruiting
N/A
120
Europe
Meyer Children's Hospital IRCCS
Acute Severe Colitis
03/25
05/25
NCT06324591: Observational Prospective Study to Identify Intestinal Microbial Profiles in Newly Diagnosed Crohn's Disease Patients

Active, not recruiting
N/A
30
Europe
Collection biological sample and analysis
Meyer Children's Hospital IRCCS
Crohn Disease
08/24
12/24
NCT06324513: Evaluation of the Efficacy and Tolerability of the Mediterranean Diet Pattern in the Exclusion Diet for Patients With Crohn's Disease.

Recruiting
N/A
120
Europe
Mediterranean Crohn's Disease Exclusion Diet (Med-CDED), Crohn's disease exclusion diet (CDED)
Meyer Children's Hospital IRCCS
Crohn Disease
07/25
10/25
DIETA-MICIREUM, NCT06862843: Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-mediated Inflammatory Pathology. Observational Multicenter Study.

Recruiting
N/A
90
Europe
Collecting questionnaires and biological samples
Meyer Children's Hospital IRCCS
Juvenile Idiopathic Arthritis (JIA), Crohn Disease (CD), Ulcerative Colitis (UC)
05/25
11/25
JIA-ED, NCT06874608: Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis

Recruiting
N/A
20
Europe
complete, polymeric formula, fiber, lactose and gluten free
Meyer Children's Hospital IRCCS
Juvenile Idiopathic Arthritis (JIA)
05/25
11/25
NCT05904938: Oral Administration of Actitan-F in Paediatric Diarrhoea

Recruiting
N/A
136
Europe
Lenodiar Pediatric, Placebo
Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions
Chronic Diarrhoea of Infants and/or Young Children
12/24
12/24
Cuzzubbo, Daniela
NCT01728155: European Low and Intermediate Risk Neuroblastoma Protocol

Completed
3
685
Europe, RoW
chemotherapy
Instituto de Investigacion Sanitaria La Fe
LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
12/22
 
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
Rosa, Camilla
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
Melani, Federico
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruemmele, Frank M
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
IMMUNOBIOTA, NCT02614911: Characterization of Phenotype and Genotype of Early Onset Enteropathies

Recruiting
N/A
1445
Europe
Biological sampling
Imagine Institute
Inflammatory Bowel Disease
06/54
06/54
Jacobson, Kevan
ViDiPeC-2, NCT03999580: The Vitamin D in Pediatric Crohn's Disease ( )

Recruiting
3
316
Canada
vitamin D3, cholecalciferol
Jantchou Prevost
Crohn Disease
12/23
12/24
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
NCT03630146: iPeer2Peer Program for Adolescents With Inflammatory Bowel Disease

Completed
N/A
150
Canada
iPeer2Peer program, Waitlist control
The Hospital for Sick Children
Inflammatory Bowel Diseases
03/22
03/22
CIDsCaNN, NCT02308917: The Canadian Children Inflammatory Bowel Disease Network

Recruiting
N/A
2400
Canada
The Hospital for Sick Children, Children's Hospital of Eastern Ontario, British Columbia Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, IWK Health Centre, Montreal Children's Hospital of the MUHC, St. Justine's Hospital, Health Sciences Centre, Winnipeg, Manitoba, Eastern Health, Children's Hospital of Western Ontario, McMaster Children's Hospital
Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
04/26
04/26
DEIVA, Kumaran
IDAR, NCT05545384 / 2022-002385-32: Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial

Recruiting
3
86
Europe
Immediate Azathioprine (1st attack), Immediate Rituximab (1st attack), Standard of care
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Acute Demyelinating Syndrome
04/27
04/30
PASTA, NCT04873583 / 2021-005571-39: High Dose Steroids in Children With Stroke

Recruiting
3
70
Europe, RoW
Methylprednisolone, Solu-Medrol, Prednisolone, Spiricort
Insel Gruppe AG, University Hospital Bern, University of Bern
Paediatric Stroke
08/25
07/26
TIM-DePisT, NCT05946486: Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

Not yet recruiting
3
174
Europe
immunomodulatory treatment by rituximab
University Hospital, Bordeaux
Mental Disorder
01/26
12/26
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27
REMYELIKIDS, NCT05258396: Exploring Cortical Remyelination in Children with Multiple Sclerosis

Recruiting
N/A
40
Europe
MRI without injection of contrast product
Assistance Publique - Hôpitaux de Paris
Children with Multiple Sclerosis
09/25
09/25
Lionetti, Paolo
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
NCT06324500: Prognostic Role of Bowel Ultrasound Scan in Children Affected by Acute Severe Colitis

Recruiting
N/A
120
Europe
Meyer Children's Hospital IRCCS
Acute Severe Colitis
03/25
05/25
NCT06324591: Observational Prospective Study to Identify Intestinal Microbial Profiles in Newly Diagnosed Crohn's Disease Patients

Active, not recruiting
N/A
30
Europe
Collection biological sample and analysis
Meyer Children's Hospital IRCCS
Crohn Disease
08/24
12/24
NCT06324513: Evaluation of the Efficacy and Tolerability of the Mediterranean Diet Pattern in the Exclusion Diet for Patients With Crohn's Disease.

Recruiting
N/A
120
Europe
Mediterranean Crohn's Disease Exclusion Diet (Med-CDED), Crohn's disease exclusion diet (CDED)
Meyer Children's Hospital IRCCS
Crohn Disease
07/25
10/25
DIETA-MICIREUM, NCT06862843: Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-mediated Inflammatory Pathology. Observational Multicenter Study.

Recruiting
N/A
90
Europe
Collecting questionnaires and biological samples
Meyer Children's Hospital IRCCS
Juvenile Idiopathic Arthritis (JIA), Crohn Disease (CD), Ulcerative Colitis (UC)
05/25
11/25
JIA-ED, NCT06874608: Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis

Recruiting
N/A
20
Europe
complete, polymeric formula, fiber, lactose and gluten free
Meyer Children's Hospital IRCCS
Juvenile Idiopathic Arthritis (JIA)
05/25
11/25
NCT05904938: Oral Administration of Actitan-F in Paediatric Diarrhoea

Recruiting
N/A
136
Europe
Lenodiar Pediatric, Placebo
Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions
Chronic Diarrhoea of Infants and/or Young Children
12/24
12/24
Cuzzubbo, Daniela
NCT01728155: European Low and Intermediate Risk Neuroblastoma Protocol

Completed
3
685
Europe, RoW
chemotherapy
Instituto de Investigacion Sanitaria La Fe
LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
12/22
 
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
Rosa, Camilla
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
Melani, Federico
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27

Download Options